{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Lung+Non-Squamous+Non-Small+Cell+Carcinoma&page=2", "query": { "condition": "Metastatic Lung Non-Squamous Non-Small Cell Carcinoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Lung+Non-Squamous+Non-Small+Cell+Carcinoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T06:21:29.404Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01313663", "title": "A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer, Small Cell" ], "interventions": [ { "name": "pazopanib", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2011-02", "completion_date": "2012-07", "has_results": true, "last_update_posted_date": "2014-10-27", "last_synced_at": "2026-06-10T06:21:29.404Z", "location_count": 25, "location_summary": "Tucson, Arizona • Skokie, Illinois • Indianapolis, Indiana + 19 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Skokie", "state": "Illinois" }, { "city": "Skokie", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Ames", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT01313663" }, { "nct_id": "NCT03094169", "title": "AVID100 in Advanced Epithelial Carcinomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Triple Negative Breast Cancer", "Head and Neck Squamous Cell Carcinoma", "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "AVID100 IV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Formation Biologics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2017-02-01", "completion_date": "2021-01-30", "has_results": true, "last_update_posted_date": "2025-06-11", "last_synced_at": "2026-06-10T06:21:29.404Z", "location_count": 10, "location_summary": "New Haven, Connecticut • Grand Rapids, Michigan • New York, New York + 6 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03094169" }, { "nct_id": "NCT03631199", "title": "Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "canakinumab", "type": "DRUG" }, { "name": "canakinumab-matching placebo", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 673, "start_date": "2018-12-21", "completion_date": "2026-01-26", "has_results": true, "last_update_posted_date": "2026-02-25", "last_synced_at": "2026-06-10T06:21:29.404Z", "location_count": 4, "location_summary": "Long Beach, California • Los Angeles, California • Orlando, Florida + 1 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03631199" }, { "nct_id": "NCT05094804", "title": "A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer", "Tumor, Solid", "Malignant Neoplasm", "Metastatic Cancer", "Advanced Solid Tumor", "Non Small Cell Lung Cancer", "Melanoma", "Head and Neck Squamous Cell Carcinoma", "Leiomyosarcoma", "Liposarcoma" ], "interventions": [ { "name": "OR2805", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OncoResponse, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 172, "start_date": "2021-09-09", "completion_date": "2024-08-15", "has_results": false, "last_update_posted_date": "2023-11-02", "last_synced_at": "2026-06-10T06:21:29.404Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Austin, Texas • San Antonio, Texas", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Austin", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05094804" }, { "nct_id": "NCT01646125", "title": "An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Non Small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "AUY922", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2012-11-23", "completion_date": "2015-11-04", "has_results": true, "last_update_posted_date": "2019-07-24", "last_synced_at": "2026-06-10T06:21:29.404Z", "location_count": 3, "location_summary": "Los Angeles, California • Rockville, Maryland • Madison, Wisconsin", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Rockville", "state": "Maryland" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01646125" }, { "nct_id": "NCT05403385", "title": "Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic NSCLC - Non-Small Cell Lung Cancer", "Locally Advanced NSCLC - Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "inupadenant", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "iTeos Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2022-08-26", "completion_date": "2025-10", "has_results": false, "last_update_posted_date": "2025-08-03", "last_synced_at": "2026-06-10T06:21:29.404Z", "location_count": 2, "location_summary": "Fayetteville, Arkansas • Tampa, Florida", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05403385" }, { "nct_id": "NCT01772004", "title": "Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1756, "start_date": "2013-01-31", "completion_date": "2019-12-16", "has_results": true, "last_update_posted_date": "2021-12-20", "last_synced_at": "2026-06-10T06:21:29.404Z", "location_count": 53, "location_summary": "Goodyear, Arizona • Scottsdale, Arizona • Rogers, Arkansas + 45 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01772004" }, { "nct_id": "NCT00988936", "title": "Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer", "Metastatic Colon/Rectum Cancer", "Non-squamous Non-small Cell Lung Cancer" ], "interventions": [ { "name": "[F-18]RGD-K5", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Siemens Molecular Imaging", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2009-09", "completion_date": "2012-05", "has_results": false, "last_update_posted_date": "2012-08-22", "last_synced_at": "2026-06-10T06:21:29.404Z", "location_count": 8, "location_summary": "Irvine, California • Los Angeles, California • Newark, New Jersey + 2 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newark", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00988936" }, { "nct_id": "NCT04777994", "title": "Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor Cancer" ], "interventions": [ { "name": "ABBV-CLS-484", "type": "DRUG" }, { "name": "Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI)", "type": "DRUG" }, { "name": "Programmed Cell Death-1 (PD-1) Inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Calico Life Sciences LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 248, "start_date": "2021-03-09", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-06-10T06:21:29.404Z", "location_count": 15, "location_summary": "Tucson, Arizona • New Haven, Connecticut • Baltimore, Maryland + 11 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04777994" }, { "nct_id": "NCT03474497", "title": "UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer", "Metastatic Melanoma", "Metastatic Renal Cell Carcinoma", "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "IL-2", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Megan Daly, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2019-05-20", "completion_date": "2026-02", "has_results": true, "last_update_posted_date": "2026-01-29", "last_synced_at": "2026-06-10T06:21:29.404Z", "location_count": 2, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03474497" } ] }